Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus.
Pharmacodynamic modeling from earlier experiments in which two ciprofloxacin-susceptible Staphylococcus aureus strains and their corresponding resistant grlA mutants were exposed to a series of ciprofloxacin (J. J. Campion, P. J. McNamara, and M. E. Evans, Antimicrob. Agents Chemother. 49:209-219, 2005) and levofloxacin (J. J. Campion et al., Antimicrob. Agents Chemother. 49:2189-2199, 2005) pharmacokinetic profiles in an in vitro system indicated that the subpopulation-specific estimated maximal killing rate constants were similar for both agents, suggesting a common mechanism of action. We propose two novel pharmacodynamic models that assign mechanisms of action to fluoroquinolones (growth inhibition or death stimulation) and compare the abilities of these models and two other maximum effect models (net effect and MIC based) to describe and predict the changes in the population dynamics observed during our previous in vitro system experiments with ciprofloxacin. A high correlation between predicted and observed viable counts was observed for all models, but the best fits, as assessed by diagnostic tests, and the most precise parameter estimates were obtained with the growth inhibition and net effect models. All models, except the death stimulation model, correctly predicted that resistant subpopulations would not emerge when a high-density culture was exposed to a high initial concentration designed to rapidly eradicate low-level-resistant grlA mutants. Additional experiments are necessary to elucidate which of the proposed mechanistic models best characterizes the antibacterial effects of fluoroquinolone antimicrobial agents.
Chung
Philip
P
Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40502, USA.
McNamara
Patrick J
PJ
Campion
Jeffrey J
JJ
Evans
Martin E
ME
D000890:Anti-Infective Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D002939:Ciprofloxacin / Q000493:pharmacokinetics* / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones / Q000493:pharmacokinetics* / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D008954:Models, Biological; D011237:Predictive Value of Tests; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification / Q000378:metabolism
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D002939:Ciprofloxacin